Phuturdex › Diseases › Primary Dysautonomias
Drugs in development · updated 30 October 2026
Primary Dysautonomias: drugs in development
As of 30 October 2026 there are 2 active clinical trials (recruiting or ongoing, phases I–III) on 4 drugs for primary Dysautonomias. 0 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Cromolyn SodiumSodium Cromoglicate, Cromoglycate | Early I | 1 | NCT07757555 |
| GuanfacineIntuniv®, Tenex® | Early I | 1 | NCT07757555 |
| ModafinilProvigil® | Early I | 1 | NCT01988883 |
| PropranololHemangeol®, Innopran Xl® | Early I | 1 | NCT01988883 |
Sorted by most advanced phase and number of active trials.
All 4 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Multiple system atrophy 19 drugs
- Postural orthostatic tachycardia syndrome 20 drugs
- Parkinson's disease 104 drugs
- Orthostatic hypotension 3 drugs
- Shy-Drager syndrome 4 drugs
- Neurodegenerative Diseases 25 drugs
- Hereditary sensory and autonomic neuropathy 6 drugs
- Tachycardia 17 drugs
- Sinus tachycardia 13 drugs
- Myalgic encephalomyelitis/chronic fatigue syndrome 7 drugs
- Post-Acute COVID-19 Syndrome 44 drugs
- Orthostatic intolerance 6 drugs
Broader categories
- Nervous System Diseases 39 drugs
- Mental disorder 24 drugs
- Neurologic Manifestations 15 drugs
- Neurocognitive Disorders 10 drugs
- Arrhythmias, Cardiac 10 drugs
- Heart disease 17 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D054969 “Primary Dysautonomias”.